- Home
- PRK vs DNLI Comparison
PRK vs DNLI Comparison
Compare PRK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRK | DNLI |
|---|---|---|
| Founded | 1908 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PRK | DNLI |
|---|---|---|
| Price | $164.07 | $17.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $178.00 | $32.58 |
| AVG Volume (30 Days) | 69.9K | ★ 1.7M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 10.85 | N/A |
| Revenue | ★ $535,826,000.00 | N/A |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $12.58 | $3,993.60 |
| P/E Ratio | $15.14 | ★ N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $137.97 | $10.57 |
| 52 Week High | $190.59 | $24.35 |
Technical Indicators
Market Signals| Indicator | PRK | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 47.26 |
| Support Level | $162.23 | $17.20 |
| Resistance Level | $165.67 | $18.30 |
| Average True Range (ATR) | 3.67 | 1.03 |
| MACD | 1.17 | -0.26 |
| Stochastic Oscillator | 86.65 | 9.22 |
Price Performance
Historical ComparisonAbout PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.